What is Chongqing Genrix Biopharmaceutical Co., Ltd.'s (688443.SS) StockRank?

MoatMap's StockRank for Chongqing Genrix Biopharmaceutical Co., Ltd. (688443.SS) is 12/100, with a Strong Sell signal. This is a composite score combining Quality (29), Value (35), and Momentum (35) factor ranks across MoatMap's 19,000+ stock universe.

Does Chongqing Genrix Biopharmaceutical Co., Ltd. have an economic moat?

Chongqing Genrix Biopharmaceutical Co., Ltd. (688443.SS) has a Quality factor score of 29/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Chongqing Genrix Biopharmaceutical Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Chongqing Genrix Biopharmaceutical Co., Ltd. (688443.SS) is Strong Sell, based on a StockRank of 12/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Chongqing Genrix Biopharmaceutical Co., Ltd. in?

Chongqing Genrix Biopharmaceutical Co., Ltd. (688443.SS) operates in the Healthcare sector, specifically the Biotechnology industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

688443.SS

STRONG SELLREMOVE

Chongqing Genrix Biopharmaceutical Co., Ltd. · Healthcare · China · $1.5B · Avg Vol: $16M/d

StockRank

P/E (TTM)

—

ROE

-32.8%

D/E

0.8x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Chongqing Genrix Biopharmaceutical is a clinical-stage biotech firm with no commercialized CDMO capabilities. It lacks the high ROIC and pricing power required for our healthcare sleeve.

COMPANY DESCRIPTION

Chongqing Genrix Biopharmaceutical Co., Ltd. develops and commercializes recombinant protein therapeutics and monoclonal antibodies, focusing on autoimmune and infectious diseases. The company features a fully integrated biopharmaceutical platform spanning early-stage R&D to large-scale commercial manufacturing. It is an emerging biotechnology player with a pipeline of biosimilars and innovative biologics targeting high-demand clinical indications.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	70,237	179,052	4M	34M	685.9%
EPS	-0.31	-0.37	-0.32	-0.22	—
Shares	275M	367M	367M	367M	+33.3%
Debt	117M	95M	124M	157M	10.3%
Equity	4M	411M	314M	234M	279.1%
Op CF	-26M	-56M	-85M	-50M	—
Inv CF	8M	18M	-63M	-50M	—
Fin CF	24M	458M	22M	27M	—

PRICE (1M)-26.8%

SMA 50SMA 200

$3.20

RSI (14)

7.9

52W High

$5.60

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

-20.0%28.5

ROE

-32.8%24.1

GP/Assets

8.6%23.4

Op. Margin

-218.5%13.5

FCF/Assets

-9.8%28.3

Piotroski

—28.8

Int. Cover

-16.1x21.0

D/E Ratio

0.83x18.4

Current Ratio

4.78x69.3

Value

P/E (TTM)

—N/A

EV/EBITDA

-14.1x84.5

P/FCF

—N/A

P/B

5.5x21.4

P/S

28.6x13.4

Div Yield

—N/A

Momentum

52W High %

57%35.1

RS 6M

-29%43.0

SMA 50/200

0.98x55.8

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-78%5.9

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$1.5B

P/E (Forward)

-7.9x

Gross Margin

92.3%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 688443.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
688443.SS	Chongqing Genrix Biopharmaceutical Co., Ltd.(you)	$1.5B	12	STRONG SELL
688382.SS	InventisBio Co., Limited	$1.7B	12	STRONG SELL
688068.SS	Beijing Hotgen Biotech Co., Ltd.	$1.2B	12	STRONG SELL
2616.HK	CStone Pharmaceuticals	$1.6B	14	STRONG SELL
300294.SZ	China Resources Boya Bio-pharmaceutical Group Co.,Ltd	$1.2B	16	STRONG SELL
300204.SZ	Staidson (Beijing) BioPharmaceuticals Co., Ltd.	$1.8B	16	STRONG SELL
2659.HK	Shanghai Bao Pharmaceuticals Co., Ltd.	$1.0B	10	STRONG SELL
6938.HK	Suzhou Ribo Life Science Co	$1.3B	5	STRONG SELL
2157.HK	Lepu Biopharma Co., Ltd.	$981M	15	STRONG SELL
2595.HK	GenFleet Therapeutics (Shanghai) Inc.	$1.6B	21	SELL

Peer medians: ROE 4.8% · P/E 27.8x · Gross margin 53.0%

Chongqing Genrix Biopharmaceutical Co., Ltd. (688443.SS) — Stock Score Summary

Chongqing Genrix Biopharmaceutical Co., Ltd. (688443.SS) has a MoatMap StockRank of 12/100 based on Quality (29/100), Value (35/100), and Momentum (35/100) factor scores. The current signal is STRONG SELL. Chongqing Genrix Biopharmaceutical is a clinical-stage biotech firm with no commercialized CDMO capabilities. It lacks the high ROIC and pricing power required for our healthcare sleeve.

Key Financial Metrics

Price	$3.20
Market Cap	$1.5B
P/E (Forward)	-7.91
Price/Book	5.50
Return on Equity	-32.8%
Return on Invested Capital	-20.0%
Debt/Equity	83.31
Gross Margin	92.3%
Operating Margin	-218.5%
Revenue Growth	233.6%
Free Cash Flow	$-6M

Chongqing Genrix Biopharmaceutical Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Chongqing Genrix Biopharmaceutical Co., Ltd.’s (688443.SS) StockRank?: MoatMap’s StockRank for Chongqing Genrix Biopharmaceutical Co., Ltd. (688443.SS) is 12/100, with a Strong Sell signal. It is a composite of Quality (29), Value (35), and Momentum (35) factor ranks across MoatMap’s 19,000+ stock universe.
Does Chongqing Genrix Biopharmaceutical Co., Ltd. have an economic moat?: Chongqing Genrix Biopharmaceutical Co., Ltd. (688443.SS) has a Quality factor score of 29/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Chongqing Genrix Biopharmaceutical Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Chongqing Genrix Biopharmaceutical Co., Ltd. (688443.SS) is Strong Sell, based on a StockRank of 12/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Chongqing Genrix Biopharmaceutical Co., Ltd. in?: Chongqing Genrix Biopharmaceutical Co., Ltd. (688443.SS) operates in the Healthcare sector, specifically the Biotechnology industry (China).